Picture

Questions?

+1-866-353-3335

SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare

PUBLISHER: Lucintel | PRODUCT CODE: 1387502

Cover Image

PUBLISHER: Lucintel | PRODUCT CODE: 1387502

T-Cell Lymphoma Market Report: Trends, Forecast and Competitive Analysis to 2030

PUBLISHED:
PAGES: 150 Pages
DELIVERY TIME: 3 business days
SELECT AN OPTION
PDF (Single User License)
USD 4850
PDF (2 Users License)
USD 5800
PDF (5 Users License)
USD 6700
PDF (Corporate License)
USD 8850

Add to Cart

T-Cell Lymphoma Trends and Forecast

The future of the global T-cell lymphoma market looks promising with opportunities in the radiotherapy, chemotherapy, immunotherapy, and stem cell transplantation markets. The global T-cell lymphoma market is expected to reach an estimated $3.3 billion by 2030 with a CAGR of 6.5% from 2024 to 2030. The major drivers for this market are rising incidence of T-cell lymphomas globally, advances in technologies related to cancer treatment, and growing usage of immunotherapies, including car-t cell therapies and immune checkpoint inhibitors.

A more than 150-page report is developed to help in your business decisions.

T-Cell Lymphoma by Segment

The study includes a forecast for the global T-cell lymphoma by type, therapy, and region.

T-Cell Lymphoma Market by Type [Shipment Analysis by Value from 2018 to 2030]:

  • Peripheral T-Cell Lymphoma
  • Cutaneous T-Cell Lymphoma
  • Anaplastic Large Cell Lymphoma
  • Angio-Immuno-Blastic T-Cell Lymphoma

T-Cell Lymphoma Market by Therapy [Shipment Analysis by Value from 2018 to 2030]:

  • Radiotherapy
  • Chemotherapy
  • Immunotherapy
  • Stem Cell Transplantation
  • Others

T-Cell Lymphoma Market by Region [Shipment Analysis by Value from 2018 to 2030]:

  • North America
  • Europe
  • Asia Pacific
  • The Rest of the World

List of T-Cell Lymphoma Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies T-cell lymphoma companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the T-cell lymphoma companies profiled in this report include-

  • Johnson & Johnson
  • Novartis
  • Bristol Myers Squibb Company
  • Merck
  • F. Hoffmann-La Roche

T-Cell Lymphoma Market Insights

Lucintel forecasts that peripheral T-cell lymphoma is expected to witness the highest growth over the forecast period because it is increasingly found in children and young adults, which is slow-growing type of lymphoma, but it can be difficult to treat.

North America will remain the largest region over the forecast period due to high T-cell lymphoma prevalence, existence of major industry participants, and rise in R&D activities.

Features of the Global T-Cell Lymphoma Market

Market Size Estimates: T-cell lymphoma market size estimation in terms of value ($B).

Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.

Segmentation Analysis: T-cell lymphoma market size by type, therapy, and region in terms of value ($B).

Regional Analysis: T-cell lymphoma market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different type, therapy, and regions for the T-cell lymphoma market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the T-cell lymphoma market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

FAQ

Q1. What is the T-cell lymphoma market size?

Answer: The global T-cell lymphoma market is expected to reach an estimated $3.3 billion by 2030.

Q2. What is the growth forecast for T-cell lymphoma market?

Answer: The global T-cell lymphoma market is expected to grow with a CAGR of 6.5% from 2024 to 2030.

Q3. What are the major drivers influencing the growth of the T-cell lymphoma market?

Answer: The major drivers for this market are rising incidence of T-cell lymphomas globally, advances in technologies related to cancer treatment, and growing usage of immunotherapies, including car-t cell therapies and immune checkpoint inhibitors.

Q4. What are the major segments for T-cell lymphoma market?

Answer: The future of the global T-cell lymphoma market looks promising with opportunities in the radiotherapy, chemotherapy, immunotherapy, and stem cell transplantation markets.

Q5. Who are the key T-cell lymphoma market companies?

Answer: Some of the key T-cell lymphoma companies are as follows:

  • Johnson & Johnson
  • Novartis
  • Bristol Myers Squibb Company
  • Merck
  • F. Hoffmann-La Roche

Q6. Which T-cell lymphoma market segment will be the largest in future?

Answer: Lucintel forecasts that peripheral T-cell lymphoma is expected to witness the highest growth over the forecast period because it is increasingly found in children and young adults, which is slow-growing type of lymphoma, but it can be difficult to treat.

Q7. In T-cell lymphoma market, which region is expected to be the largest in next 5 years?

Answer: North America will remain the largest region over the forecast period due to high T-cell lymphoma prevalence, existence of major industry participants, and rise in R&D activities.

Q.8 Do we receive customization in this report?

Answer: Yes, Lucintel provides 10% customization without any additional cost.

This report answers following 11 key questions:

  • Q.1. What are some of the most promising, high-growth opportunities for the T-cell lymphoma market by type (peripheral T-cell lymphoma, cutaneous T-cell lymphoma, anaplastic large cell lymphoma, and angio-immuno-blastic T-cell lymphoma), therapy (radiotherapy, chemotherapy, immunotherapy, stem cell transplantation, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
  • Q.2. Which segments will grow at a faster pace and why?
  • Q.3. Which region will grow at a faster pace and why?
  • Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
  • Q.5. What are the business risks and competitive threats in this market?
  • Q.6. What are the emerging trends in this market and the reasons behind them?
  • Q.7. What are some of the changing demands of customers in the market?
  • Q.8. What are the new developments in the market? Which companies are leading these developments?
  • Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
  • Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
  • Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Global T-Cell Lymphoma Market : Market Dynamics

  • 2.1: Introduction, Background, and Classifications
  • 2.2: Supply Chain
  • 2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2018 to 2030

  • 3.1. Macroeconomic Trends (2018-2023) and Forecast (2024-2030)
  • 3.2. Global T-Cell Lymphoma Market Trends (2018-2023) and Forecast (2024-2030)
  • 3.3: Global T-Cell Lymphoma Market by Type
    • 3.3.1: Peripheral T-cell Lymphoma
    • 3.3.2: Cutaneous T-cell Lymphoma
    • 3.3.3: Anaplastic Large Cell Lymphoma
    • 3.3.4: Angio-Immuno-blastic T-cell Lymphoma
  • 3.4: Global T-Cell Lymphoma Market by Therapy
    • 3.4.1: Radiotherapy
    • 3.4.2: Chemotherapy
    • 3.4.3: Immunotherapy
    • 3.4.4: Stem Cell Transplantation
    • 3.4.5: Others

4. Market Trends and Forecast Analysis by Region from 2018 to 2030

  • 4.1: Global T-Cell Lymphoma Market by Region
  • 4.2: North American T-Cell Lymphoma Market
    • 4.2.2: North American T-Cell Lymphoma Market by Therapy: Radiotherapy, Chemotherapy, Immunotherapy, Stem Cell Transplantation, and Others
  • 4.3: European T-Cell Lymphoma Market
    • 4.3.1: European T-Cell Lymphoma Market by Type: Peripheral T-cell Lymphoma, Cutaneous T-cell Lymphoma, Anaplastic Large Cell Lymphoma, and Angio-Immuno-blastic T-cell Lymphoma
    • 4.3.2: European T-Cell Lymphoma Market by Therapy: Radiotherapy, Chemotherapy, Immunotherapy, Stem Cell Transplantation, and Others
  • 4.4: APAC T-Cell Lymphoma Market
    • 4.4.1: APAC T-Cell Lymphoma Market by Type: Peripheral T-cell Lymphoma, Cutaneous T-cell Lymphoma, Anaplastic Large Cell Lymphoma, and Angio-Immuno-blastic T-cell Lymphoma
    • 4.4.2: APAC T-Cell Lymphoma Market by Therapy: Radiotherapy, Chemotherapy, Immunotherapy, Stem Cell Transplantation, and Others
  • 4.5: ROW T-Cell Lymphoma Market
    • 4.5.1: ROW T-Cell Lymphoma Market by Type: Peripheral T-cell Lymphoma, Cutaneous T-cell Lymphoma, Anaplastic Large Cell Lymphoma, and Angio-Immuno-blastic T-cell Lymphoma
    • 4.5.2: ROW T-Cell Lymphoma Market by Therapy: Radiotherapy, Chemotherapy, Immunotherapy, Stem Cell Transplantation, and Others

5. Competitor Analysis

  • 5.1: Product Portfolio Analysis
  • 5.2: Operational Integration
  • 5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

  • 6.1: Growth Opportunity Analysis
    • 6.1.1: Growth Opportunities for the Global T-Cell Lymphoma Market by Type
    • 6.1.2: Growth Opportunities for the Global T-Cell Lymphoma Market by Therapy
    • 6.1.3: Growth Opportunities for the Global T-Cell Lymphoma Market by Region
  • 6.2: Emerging Trends in the Global T-Cell Lymphoma Market
  • 6.3: Strategic Analysis
    • 6.3.1: New Product Development
    • 6.3.2: Capacity Expansion of the Global T-Cell Lymphoma Market
    • 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global T-Cell Lymphoma Market
    • 6.3.4: Certification and Licensing

7. Company Profiles of Leading Players

  • 7.1: Johnson & Johnson
  • 7.2: Novartis
  • 7.3: Bristol Myers Squibb Company
  • 7.4: Merck
  • 7.5: F. Hoffmann-La Roche
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Hi, how can we help?
Contact us!